Clatterbridge Pharmacy Limited v The Commissioners for HMRC
Decision date: 5 June 2025
Neutral citation: [2025] UKFTT 661 (TC)
Overall AI summary confidence: high
Short overview
This short overview is intended to summarise the case, issues and outcome so far as they are supported by the judgment.
AI confidence in this short overview: high
This appeal concerned whether intravenous and injectable cancer medicines dispensed by Clatterbridge Pharmacy Ltd to named outpatients for use at home qualified for zero rating under Schedule 8, Group 12, Item 1 VATA, specifically the meaning of "personal use". The Tribunal held that "personal use" means use by a named individual patient and does not require the patient to self‑administer, and therefore allowed CPL's appeal.
Ratio decidendi
This summary is intended to identify the ratio decidendi, meaning the legal reasons for deciding and the binding part of the decision.
AI confidence in this ratio decidendi summary: high
The Tribunal applied the ordinary (natural) meaning of undefined statutory words, informed by context and the schedule notes, and concluded that Note 5A operates as an exclusion for supplies on hospital or nursing‑home premises without narrowing the ordinary meaning of "personal use" beyond that exclusion; thus a supply to a named patient for use at home qualifies even if administration is by a healthcare professional.
Obiter dicta
This summary is intended to identify obiter dicta, meaning observations made by the way that were not necessary to deciding the case and are not binding.
AI confidence in this obiter dicta summary: medium
The judgment suggested that HMRC's alternative approach—equating "personal" with "private" self‑administration—would produce uncertain results as clinical practice changes and could lead to absurdities if zero‑rating turned on transient clinical practices such as formal "sign‑off" for self‑administration.